Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy

Hepatitis

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Gut.

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA

doi: 10.1136/gutjnl-2019-318981.

Hepatitis

HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy

Hepatology

Mak LY, Cloherty G, Wong DK, Gersch J, Seto WK, Fung J, Yuen MF

doi: 10.1002/hep.31616

HepatitisHepatology

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

J Gastroenterol Hepatol

Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N

doi: 10.1111/jgh.15563

Hepatitis

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Lancet Gastroenterol Hepatol.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos , Crans G, Flaherty J, Gaggar A, Marcellin P

doi: 10.1016/S2468-

Hepatitis

Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B

Clin Infect Dis.

Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA

doi: 10.1093/cid/ciaa013.

Hepatitis

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

BMC Gastroenterol

Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF

doi: 10.1186/s12876-021-01711-x

HepatitisHepatology

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Clin Gastroenterol Hepatol.

Chang ML, Cheng JS, Chien RN, Liaw YF

doi: 10.1016/j.cgh.2020.01.018.

Hepatitis

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Gastroenterology.

Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A

doi: 10.1053/j.gastro.2020.02.058.

Hepatitis

Effects of Hepatitis B Surface Antigen on Virus-specific and Global T Cells in Patients With Chronic HBV infection

Gastroenterology.

Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZM, Ahmad R, Cheng Y, Dutertre CA, Heinecke A, Rivino L, Tan A, Hansi NK, Zhang M, Xi S, Chong Y, Pflanz S, Newell EW, Kennedy PTF, Bertoletti A

doi: 10.1053/j.gastro.2020.04.019.

Related content

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Effects of Hepatitis B Surface Antigen on Virus-specific and Global T Cells in Patients With Chronic HBV infection